Security Snapshot

TG THERAPEUTICS, INC. - Common Stock (TGTX) Institutional Ownership

CUSIP: 88322Q108

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

302

Shares (Excl. Options)

66,444,336

Price

$54.94

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+896,911
Value change
+$53,211,584
Number of holders
302
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
159,699,810
SEC-reported price per share
$57.12
Insider filing price
$57.12
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • TGTX - TG THERAPEUTICS, INC. - Common Stock is tracked under CUSIP 88322Q108.
  • 302 institutions reported positions in Q2 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 362 to 302 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $3,499,379,007 to $3,651,207,169.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 302 institutions filings for Q2 2026.

Open SEC evidence

Security key

88322Q108

Latest holder period

Q2 2026

13F holders

302

13D/G owners

3

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
3
Security
TGTX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 13% $883,115,925 20,134,882 BlackRock, Inc. 31 Mar 2025
VANGUARD PORTFOLIO MANAGEMENT LLC 5.3% $279,054,976 8,400,210 Vanguard Portfolio Management 31 Mar 2026
STATE STREET CORP 5.1% +8% $292,634,861 +$24,085,260 8,100,619 +9% STATE STREET CORPORATION 30 Sep 2025

As of 30 Jun 2026, 302 institutional investors reported holding 66,444,336 shares of TG THERAPEUTICS, INC. - Common Stock (TGTX). This represents 42% of the company’s total 159,699,810 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
53%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 14% 22,050,045 -0.91% 0.02% $1,211,429,475
VANGUARD PORTFOLIO MANAGEMENT LLC 5% 7,963,266 -3.8% 0.02% $437,501,834
STATE STREET CORP 4.9% 7,786,471 -10% 0.01% $427,788,717
VANGUARD CAPITAL MANAGEMENT LLC 3.9% 6,149,403 -6.9% 0.01% $337,848,201
GEODE CAPITAL MANAGEMENT, LLC 2.3% 3,642,216 +4.1% 0.01% $200,135,578
D. E. Shaw & Co., Inc. 2.1% 3,400,808 +476% 0.12% $186,840,392
Soleus Capital Management, L.P. 1.8% 2,927,895 -27% 5.5% $160,858,551
PRICE T ROWE ASSOCIATES INC /MD/ 1.7% 2,767,656 +337% 0.02% $152,056,000
Clearbridge Investments, LLC 1.7% 2,650,192 -17% 0.12% $145,601,554
CONGRESS ASSET MANAGEMENT CO 1.6% 2,600,123 +20% 0.88% $142,850,758
TWO SIGMA INVESTMENTS, LP 1.5% 2,468,971 +60% 0.1% $135,645,267
GOLDMAN SACHS GROUP INC 1.4% 2,314,279 +1.2% 0.01% $127,146,488
Pictet Asset Management Holding SA 1.1% 1,785,951 +2.2% 0.09% $98,120,148
JANE STREET GROUP, LLC 1.1% 1,752,646 -14% 0.06% $96,290,371
Nuveen, LLC 1% 1,625,876 +12% 0.02% $89,325,628
MORGAN STANLEY 1% 1,601,714 +14% 0% $87,998,254
Hood River Capital Management LLC 1% 1,600,510 +2% 0.64% $87,932,019
NORTHERN TRUST CORP 0.96% 1,537,059 +6.5% 0.01% $84,446,021
Sixth Street Partners Management Company, L.P. 0.82% 1,313,103 0.01% $72,141,879
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.82% 1,313,103 +1.4% 0.01% $72,141,879
BANK OF AMERICA CORP /DE/ 0.82% 1,309,788 -10% 0% $71,959,753
DIMENSIONAL FUND ADVISORS LP 0.76% 1,210,578 +12% 0.01% $66,512,573
FMR LLC 0.64% 1,018,814 +263% 0% $55,973,620
VANGUARD FIDUCIARY TRUST CO 0.6% 961,750 -0.71% 0.01% $52,838,545
BARCLAYS PLC 0.6% 957,848 +721% 0.02% $52,624,168

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 66,444,336 $3,651,207,169 +$53,211,584 $54.94 302
2026 Q1 105,367,277 $3,499,379,007 +$72,887,215 $33.22 362
2025 Q4 103,112,079 $3,073,945,066 +$87,945,935 $29.81 349
2025 Q3 99,013,834 $3,576,956,736 -$93,583,862 $36.12 351
2025 Q2 101,251,004 $3,644,068,318 +$105,165,687 $35.99 353
2025 Q1 98,398,350 $3,879,797,019 +$91,891,626 $39.43 370
2024 Q4 96,867,606 $2,915,819,583 -$82,204,584 $30.10 325
2024 Q3 101,373,709 $2,371,765,800 -$15,722,787 $23.39 299
2024 Q2 93,092,725 $1,656,135,243 +$59,195,672 $17.79 249
2024 Q1 90,107,125 $1,370,540,354 -$16,725,794 $15.21 234
2023 Q4 90,283,479 $1,542,093,372 +$61,590,148 $17.08 228
2023 Q3 90,485,069 $756,218,410 -$269,126,636 $8.36 230
2023 Q2 88,259,288 $2,192,377,673 -$88,730,550 $24.84 240
2023 Q1 94,743,370 $1,424,911,575 +$49,874,888 $15.04 207
2022 Q4 93,352,835 $1,104,363,051 -$26,457,664 $11.83 194
2022 Q3 98,647,609 $583,969,618 -$39,974,731 $5.92 168
2022 Q2 106,408,531 $452,245,708 -$5,017,128 $4.25 161
2022 Q1 100,868,318 $959,384,130 -$98,040,474 $9.51 169
2021 Q4 100,212,572 $1,902,689,658 +$38,904,536 $19.00 185
2021 Q3 96,326,356 $3,203,956,013 -$38,579,975 $33.28 213
2021 Q2 96,046,069 $3,725,506,174 -$125,135,262 $38.79 232
2021 Q1 98,807,721 $4,765,076,153 -$16,595,617 $48.20 233
2020 Q4 99,923,648 $5,198,116,671 +$669,912,268 $52.02 246
2020 Q3 87,699,838 $2,345,820,172 +$119,192,436 $26.76 180
2020 Q2 83,924,060 $1,633,423,112 +$391,433,047 $19.48 172
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .